Thylakoids for Health & Longevity

Evidence Review created on 09/27/2026 using AI4L + evidence-mcp / GPT 6

Also known as: Thylakoid Membranes, Green-Plant Membranes, Spinach-Derived Thylakoids, Thylakoid-Rich Spinach Extract, Appethyl

Motivation

Thylakoids are tiny membranes in green plants that help capture light. For human use, they are usually concentrated from spinach and sold as oral supplements. Interest in these preparations centers on appetite, eating behavior, and body weight. Their proposed action involves the handling of food within the digestive tract, connecting a plant structure to questions about how meals influence fullness and subsequent eating.

Research began with experiments on fat digestion and later moved to human meal tests and longer weight-management studies. Investigators have examined concentrated extracts alongside changes in diet and exercise, including studies in people with excess weight. This history makes the identity of the preparation and the habits surrounding its use relevant to interpreting the evidence. A concentrated membrane extract is also a different subject from eating spinach as part of a varied diet.

This review examines the benefits, uncertainties, safety considerations, and research protocols for thylakoids through a health and longevity lens. It distinguishes changes in appetite and blood tests from claims about disease prevention and lifespan.

Benefits - Risks - Protocol - Conclusion

These sources explain appetite regulation, research history, and hedonic hunger (eating driven by food reward).

FoundMyFitness returned brief outbound research headlines, not a substantive overview. Independent web and on-site searches found no qualifying thylakoid-specific discussion from Attia, Kresser, or Lifespan.io. Five qualifying sources are listed.

Grokipedia

Thylakoid

Explains the plant structures and photosynthesis underlying the name. It is biological background, not evidence that oral supplements improve human health or lifespan.

Examine

A dedicated Examine page exists, but its research content requires membership. No accessible dedicated article is linked here.

ConsumerLab

No dedicated ConsumerLab article on thylakoids was found. Its search returned broader greens and appetite-supplement articles; these do not establish independent testing of a thylakoid product.

Systematic Reviews

These systematic reviews (structured syntheses of relevant studies) summarize appetite and weight findings from randomized controlled trials (studies assigning participants by chance to an intervention or comparison), including a meta-analysis (statistical pooling) with dose-response analysis (how effects vary with dose); long-term safety lacks a dedicated review.

Mechanism of Action

Thylakoids are membranes inside chloroplasts (the light-harvesting structures of plant cells). The oral intervention studied here is a concentrated membrane-rich extract, usually from spinach, Spinacia oleracea. It contains proteins, lipids, and pigments; ordinary spinach powder and chlorophyll supplements are not equivalent preparations.

  • Delayed fat digestion: Membranes interact with fat droplets and pancreatic lipase/colipase (the enzyme and helper protein that digest fat). Laboratory and animal work shows slower fat breakdown, potentially prolonging the delivery of fat-derived signals along the intestine. The original experiments established plausibility, not human longevity benefits.
  • Appetite signaling: A human meal study reported changes in cholecystokinin (a gut hormone promoting fullness) and ghrelin (a hunger-promoting hormone). Another trial measured increased GLP-1 (glucagon-like peptide-1, a hormone affecting appetite and blood sugar). These responses do not establish equivalence to prescription appetite medications.
  • Competing explanations: Gut contents, meal composition, and dietary restriction may explain some observed effects. A human stool study did not demonstrate increased fat loss in stools; bacterial changes do not establish better gut health.

The proposed action is mainly within the digestive tract. Human absorption of intact membranes, systemic tissue distribution, elimination half-life, and drug-metabolizing pathways have not been characterized. Digestion breaks the mixture into ordinary nutritional components; no single molecular target or blood concentration defines its dose.

Historical Context & Evolution

Thylakoids originally attracted scientific attention as plant structures essential for photosynthesis. Their use as an oral supplement arose from a different question: whether biological membranes could slow fat digestion and extend intestinal fullness signals. The 2007 laboratory and rat experiments demonstrated enzyme inhibition, reduced food intake, and altered appetite hormones. Small human meal studies subsequently examined hormone responses and subjective hunger.

Commercialization centered on concentrated spinach extracts such as Appethyl. A 2014 trial reported greater weight loss in women, but its later reanalysis weakened that claim. The 2023 European Food Safety Authority assessment describes the corrected nonsignificant (not distinguishable from chance under the study’s statistical test) weight comparison, a larger trial with a small difference, and a favorable but unreplicated maintenance study. This assessment concerns a submitted product claim; it does not erase the original measurements or establish that every thylakoid preparation is ineffective.

Research broadened to women with polycystic ovary syndrome (a hormonal condition often involving irregular ovulation), then to men with obesity undergoing structured exercise. The newer studies examined blood markers as well as body composition. Several publications share a study registration and cannot be counted as independent replications. The evolving picture separates reproducible short-term appetite ratings from disputed sustained weight effects and still-unmeasured longevity outcomes.

Expected Benefits

High 🟩 🟩 🟩

Short-term hunger and fullness

A meta-analysis of five randomized controlled trials found small improvements in appetite ratings. A visual analogue scale (a line on which participants mark symptom intensity) measures experience, not calories consumed. Delayed digestion and gut hormone signaling are plausible mechanisms; most participants had excess weight. This grade reflects replicated human symptoms, not large effects or proof of sustained weight control. Nikrad et al..

Magnitude: Average hunger was 2.42 mm lower and fullness 4.60 mm higher on a 100-mm appetite scale. The 95% confidence intervals (ranges expressing statistical uncertainty) were −3.54 to −1.29 mm and +2.36 to +6.85 mm, respectively. A 60-person meal trial found no significant reduction in dinner intake.

Medium 🟩 🟩

No additional benefit reaches Medium: weight and blood-marker outcomes are conflicting or indirect, while proposed disease and longevity benefits lack clinical outcome trials.

Low 🟩

Weight and body-fat management ⚠️ Conflicted

Trials report both favorable and null results under different dietary conditions. The early weight-loss trial lost statistical significance after correction; other trials support an effect, and an unpublished maintenance study was favorable. Overall, weight benefit remains plausible but inconsistent. Claim assessment.

Magnitude: Early mean losses were 5.0 versus 3.5 kg over 12 weeks, but the corrected comparison was nonsignificant. A larger trial showed 0.53–1.0 kg additional loss, depending on analysis; a 24-week maintenance study showed −1.03 versus +0.95 kg. In women with polycystic ovary syndrome, losses were 6.97 versus 3.19 kg alongside calorie restriction (a diet providing fewer calories).

Food cravings ⚠️ Conflicted

A trial in overweight women reported less desire for palatable foods, potentially through gut-to-brain signaling. Another mixed-sex trial found no change in food wanting or liking four hours later. Timing and measurement differed; a consistent practical reduction in cravings remains uncertain.

Magnitude: The women’s trial reported 36% lower snack-and-sweet cravings, but measured food intake did not significantly decrease. The mixed-sex study found smaller salty/savory craving scores over two hours without a later food-reward effect.

Blood lipids ⚠️ Conflicted

Some trials report lower LDL cholesterol (low-density lipoprotein cholesterol, carried in particles contributing to artery plaque). However, the regulatory assessment of the larger commercial trial found no lipid difference, and exercise research found no added metabolic advantage over training. Overall, lipid effects are inconsistent and do not establish cardiovascular protection.

Magnitude: In one 12-week male cohort, LDL fell from 125.56 to 121.41 mg/dL with supplementation alone, versus 125.22 to 125.02 mg/dL in controls. These are group means, not an adjusted treatment estimate (a comparison accounting for baseline differences); exercise produced larger changes.

Glucose regulation ⚠️ Conflicted

Polycystic ovary syndrome research improved insulin without fasting-glucose benefit. A 20-woman meal trial found less late glucose decline; another found higher two-hour glucose, and exercise research showed no added metabolic benefit. Meal timing and context differ; durable glucose benefit remains uncertain.

Magnitude: Fasting insulin fell by 5.40 versus 1.19 μU/mL over 12 weeks in the women’s trial; fasting glucose changed by −0.43 versus −0.48 mg/dL. Lower insulin alone does not demonstrate prevention of diabetes. In the acute trial, less glucose decline occurred from 90 minutes after a carbohydrate-rich breakfast; fewer symptomatic low-glucose episodes were not established.

Speculative 🟨

Gut and inflammatory health

A small human study found bacterial changes, and another examined gut-related blood markers. These are not validated evidence of fewer digestive symptoms, infections, or inflammatory disease.

Hormonal and reproductive health

Testosterone and related measurements changed in women with polycystic ovary syndrome. Improved ovulation, fertility, and long-term hormonal symptoms were not established; those benefits remain extrapolations from blood tests.

Protection from oxidative damage and improved recovery ⚠️ Conflicted

Exercise research reported antioxidant-marker changes; another cohort found none. Overall, these inconsistent laboratory findings do not establish improved recovery, performance, or disease protection.

Longer healthy lifespan

Appetite regulation and metabolic changes provide a possible indirect rationale. No controlled human study establishes longer life, fewer major age-related diseases, or slower biological aging from thylakoid supplementation.

Benefit-Modifying Factors

  • Baseline weight and biomarkers: Most trials enrolled adults with excess weight; abnormal lipids or insulin offer more scope for measurable change. Benefits in lean adults with already favorable results are uncertain.
  • Sex: Early appetite and weight trials predominantly studied women; newer exercise trials studied men. Differences in craving responses are exploratory, not a basis for sex-specific dosing.
  • Health conditions: The favorable calorie-restriction trial in polycystic ovary syndrome cannot establish equivalent effects in diabetes or otherwise healthy adults. Disease-specific symptom improvements remain unproven.
  • Age: Evidence mainly concerns young to middle-aged adults, with some studies extending into the 60s. Preservation of strength and adequate food intake become particularly important when considering appetite suppression in older adults.
  • Genetics: No replicated genetic variant predicts response or defines an effective dose; commercial genetic testing has no established role.
  • Meal and activity context: Fat content, timing, dietary restriction, and exercise differ across trials. A benefit on top of sustained training is less certain than a change relative to an inactive control.

Potential Risks & Side Effects

Short studies provide limited reassurance. The 12-week women’s trial reported no adverse events; the 2026 exercise trial reported no serious events requiring withdrawal. Neither excludes uncommon harms or consequences of years of use.

High 🟥 🟥 🟥

No risk reaches High: replicated human trials have not established a treatment-attributable adverse clinical outcome.

Medium 🟥 🟥

No risk reaches Medium: reported symptoms lack clear attribution, and laboratory shifts and ingredient-based hazards do not establish a controlled clinical harm signal.

Low 🟥

Headache reported during trials

One participant in a 60-person crossover study (participants received both treatments) had a severe headache attributed by her to room temperature. Another meal trial reported mild headaches in both conditions. These observations do not establish supplement causation.

Magnitude: One severe event among 60 enrolled participants in the first study; the second reported mild headache on one treatment versus two placebo occasions. These counts do not estimate an increased risk caused by thylakoids.

Nausea during meal testing

Mild nausea occurred during or after a snack buffet in a meal trial. Events occurred with both extract and placebo, so the study does not establish a treatment-attributable increase.

Magnitude: Two treatment versus three placebo occasions; 22 women completed the crossover trial. No serious adverse events were reported in that study.

Allergy to residual spinach proteins

A spinach allergy case report documents hives and deeper tissue swelling. This is indirect evidence for membrane extracts: residual proteins and other ingredients vary, and no thylakoid-specific allergy rate is established.

Magnitude: Not quantified in available studies. Case reports lack a denominator and concentrated extracts have not undergone adequate allergy-incidence testing.

Unfavorable glucose response after meals

The acute meal trial found higher glucose two hours after thylakoids than placebo, possibly reflecting altered nutrient delivery. Long-term deterioration of glucose control was not demonstrated; the clinical importance of that isolated measurement is unknown.

Magnitude: With 5 g extract at lunch, the fasting-to-two-hour glucose rise was greater than with placebo. The publication plots this outcome without tabulating its numerical between-condition difference; the incidence of clinically harmful glucose deterioration was not measured.

Speculative 🟨

Impaired nutrient absorption

Slower digestion could interfere with nutrient availability. This remains a mechanistic concern; human stool measurements did not show steatorrhea (excess fat in stools).

Reduced oral drug exposure

A calcium-containing extract reduced ciprofloxacin absorption in rats. Human treatment failures have not been demonstrated, but drug binding is plausible and depends on the product’s mineral content.

Inadequate energy intake

Appetite suppression could worsen undernutrition or interfere with maintaining muscle during calorie restriction. This is a physiological inference; trials have not established a thylakoid-attributable incidence of malnutrition or muscle loss.

Product-dependent spinach constituents

Residual vitamin K or oxalate (a stone-forming compound) could matter with warfarin or a history of calcium-oxalate stones. These are composition-based concerns, not demonstrated harms of every thylakoid extract; purified products and whole spinach differ.

Risk-Modifying Factors

  • Genetics: No validated genetic susceptibility test exists for thylakoid toxicity or interactions.
  • Baseline status: Low weight, declining strength, poor intake, or low nutrient stores could increase the consequences of appetite suppression. Elevated glucose makes uncertain meal-related glucose effects more relevant.
  • Sex: No reliable sex-specific adverse-event rate exists. Pregnancy and breastfeeding have not been adequately studied at supplemental doses.
  • Health conditions: Spinach allergy, impaired digestion or absorption, delayed stomach emptying, and recurrent calcium-oxalate stones warrant distinct product-specific consideration; these are not all proven contraindications to purified membranes.
  • Age: Frailty and multiple medications make older adults less comparable to trial participants. Long-term nutritional and interaction risks are largely unmeasured.

Key Interactions & Contraindications

No formal human interaction program has defined a complete interaction list. The following distinguish animal evidence and ingredient-based inferences from established clinical events.

  • Antibiotics — caution: Ciprofloxacin (a medicine for bacterial infections) exposure fell in rats given a calcium-containing extract, potentially weakening infection control. Human effects are untested. Product mineral content matters; separation follows the antibiotic’s instructions. Animal pharmacokinetic study.
  • Other mineral-sensitive medicines — caution: Minerals may reduce absorption and weaken effects of tetracyclines (infection medicines such as doxycycline), thyroid replacement (levothyroxine), or osteoporosis (bone-fragility) medicines (alendronate). Extract-specific effects are untested; medicine-specific separation rules apply when relevant minerals are present.
  • Warfarin — monitor: Variable residual vitamin K could destabilize anticoagulation (prevention of blood clotting), potentially increasing clotting or bleeding risk as intake changes. Consistent product composition and clinician-managed clotting-test checks after changes address this untested, composition-based concern.
  • Glucose-lowering medicines — monitor: Insulin and sulfonylureas (insulin-releasing medicines such as glipizide) can cause low blood sugar if food intake falls. Additive effects with thylakoids are untested; established glucose monitoring becomes relevant when eating patterns change.
  • Other weight interventions — caution: GLP-1 receptor agonists (appetite-hormone medicines such as semaglutide) and orlistat could compound reduced intake or digestive effects. These combinations are untested; symptom and intake monitoring address possible intolerance.
  • Over-the-counter products — caution: Orlistat sold without prescription could add digestive intolerance or reduced nutrient absorption through overlapping fat-digestion effects. The combination is untested; symptom and nutrition monitoring address this concern. No direct interaction with acetaminophen or ibuprofen is established.
  • Supplements — caution: Psyllium or glucomannan could add fullness or digestive discomfort; berberine could add glucose lowering, potentially causing low blood sugar. These combinations are untested; changing one product at a time and tracking intake, symptoms, and glucose makes changes interpretable.

Populations who should avoid Thylakoids:

  • People with known allergy to spinach or another product ingredient.
  • Pregnant or breastfeeding people and children: supplemental-dose safety is unestablished; this exclusion does not concern usual spinach food intake.
  • People who are underweight—body mass index (weight relative to height) below 18.5 kg/m²—or have active eating disorders, undernutrition, or ongoing unintentional weight loss: appetite suppression conflicts with adequate intake. The product dossier specifically excludes underweight adults.

Other trial exclusions, including diabetes and significant digestive disease, identify evidence gaps rather than automatically proving an absolute contraindication.

Risk Mitigation Strategies

  • Product matching: A documented membrane-rich extract and lot-specific identity testing reduce the risk of substituting an unrelated spinach product or an extract with unknown composition.
  • Allergy response: Discontinuation after hives or swelling limits re-exposure; tongue swelling, breathing difficulty, or collapse are emergency symptoms. There is no validated safe rechallenge protocol.
  • Food-intake tracking: Weekly review of weight, meal completion, and strength can detect unwanted appetite suppression. Intentional fat loss and declining functional capacity are different outcomes.
  • Digestive review: Recording symptoms during the first one to two weeks helps identify persistent intolerance. Ongoing vomiting, diarrhea, or inability to maintain food intake is incompatible with continuing an elective supplement experiment.
  • Medication review: Checking mineral and vitamin K content against current medicines addresses binding and anticoagulation concerns. Drug-specific timing and monitoring take precedence over generic supplement schedules.
  • Dose restraint: Trials commonly use 5 g/day. Escalation beyond studied preparations and doses has no established additional benefit and increases exposure to unknown nutritional and interaction risks.

Therapeutic Protocol

  • Evidence-based description: No established longevity regimen or leading-practitioner standard was identified. The following describes research use, not a validated treatment prescription.
  • Usual research dose: Many studies administered 5 g/day of concentrated thylakoid-rich spinach extract for 12 weeks. This is extract mass, not 5 g of pure thylakoid membranes. Women’s trial.
  • Timing: Studies used a single dose before breakfast or roughly 30 minutes before lunch. Meal association fits the digestive mechanism; no comparison establishes a superior time of day. Male trial.
  • Single versus divided doses: Most published regimens used once-daily powder; one commercial trial divided capsules between breakfast and lunch. Comparative superiority is unknown. Regulatory assessment.
  • Alternative approaches: Appethyl and other membrane-rich extracts have been studied with dietary restriction or structured exercise. Whole spinach is a food-based alternative, but its portion size cannot be converted into an equivalent trial dose.
  • Half-life: No clinically established half-life exists for this membrane mixture. Meal effects lasting hours do not define elimination half-life or justify repeated dosing.
  • Genetics: No genetically guided dose adjustment has been established.
  • Sex: Both sexes have been studied, with uneven representation across protocols. No validated sex-specific dose exists.
  • Age: No established dose adjustment exists for older adults. Frailty, low intake, or declining muscle function changes the suitability of an appetite-focused regimen.
  • Baseline markers: Excess weight or elevated insulin characterized many participants; normal values do not justify dose escalation. No laboratory cutoff identifies responders.
  • Health conditions: The polycystic ovary syndrome findings used concurrent calorie restriction. Diabetes, significant kidney or liver disease, and impaired nutrient absorption lack validated dosing protocols.

Discontinuation & Cycling

  • Duration: Research generally spans single meals to 12 weeks, with a commercial 24-week maintenance study. Lifelong use has not been evaluated adequately. Assessment.
  • Withdrawal: No recognized withdrawal syndrome is established. Appetite may return toward baseline after stopping, but rebound hunger or weight regain specifically caused by withdrawal has not been quantified.
  • Tapering: No evidence-based taper exists; trial regimens do not establish a physiological need for gradual discontinuation.
  • Cycling: No controlled evidence supports cycling to preserve efficacy. Scheduled breaks are not a demonstrated longevity strategy.

Sourcing and Quality

  • Identity: Appethyl is a researched proprietary ingredient, not a guarantee that every finished product matches the trial material. Generic spinach, red-spinach nitrate extracts, and chlorophyll products are different interventions.
  • Standardization: The claim dossier reported substantial batch variability in membrane content and standardization by laboratory fat-digesting-enzyme inhibition. Green color or chlorophyll content alone cannot establish equivalent activity.
  • Independent testing: Useful documentation includes lot-specific identity, membrane-rich extract amount, heavy metals, pesticide residues, microbes, and relevant mineral content from an independent laboratory. No independently verified brand ranking was identified.
  • Formulation: Full ingredient disclosure matters for allergies, vitamin K, calcium, and oxalate exposure. Additional appetite agents create a different intervention from the single-extract trials.
  • Storage: Dry, sealed storage consistent with the label and expiry date limits degradation. Storage research shows that processing and storage affect pigment stability and physical function.

Practical Considerations

  • Time to effect: Hunger ratings can change within hours, while body-weight trials evaluate weeks to months. An acute feeling of fullness does not establish sustained fat loss.
  • Common pitfalls: Confusing percentage changes in craving scores with percentage weight loss exaggerates benefit. Counting multiple publications from one cohort likewise exaggerates independent confirmation.
  • Regulatory context: These preparations are marketed as supplements, not established medicines for extending lifespan. The 2023 European assessment did not substantiate the submitted Appethyl weight-reduction claim; this is an efficacy assessment, not a blanket safety ban.
  • Resources and access: Identifiable, documented extracts are less ubiquitous than ordinary spinach powders. No stable current price or cost-effectiveness advantage is established; effectiveness and composition matter more than price comparisons.
  • Commercial bias: Much early work involved the ingredient’s commercial network. The regulatory assessment also considered applicant-supplied unpublished studies, making selective publication and formulation-specific claims relevant when interpreting the literature.

Interaction with Foundational Habits

  • Sleep: No direct sleep benefit or disruption has been established. Hunger changes could indirectly affect evening eating, but no trial supports bedtime dosing or a sleep-specific protocol.
  • Nutrition: Potentially supportive of calorie restriction through fullness, but not a substitute for adequate protein, fiber, and dietary variety. Appetite suppression can oppose muscle preservation when intake is already low; most weight trials combined supplementation with dietary measures.
  • Exercise: Evidence for additional benefit is uncertain. Razi et al., 2026 found no clear metabolic superiority of supplement plus training over training alone. Neither improved performance nor impaired training adaptation is established; under-fueling is a practical concern if appetite declines.
  • Stress management: No direct effect on stress or stress hormones has been established. Associations between emotional eating and craving responses are exploratory; the craving trial does not demonstrate treatment of stress-related eating disorders.

Monitoring Protocol & Defining Success

Baseline documentation includes weight, waist, appetite, food intake, medications, digestive symptoms, and recent glucose and lipid results. No thylakoid-specific laboratory target is established; practitioner ranges in the table are contextual preferences, not proven longevity targets.

An illustrative schedule checks symptoms and intake at one to two weeks, weight and waist monthly, and relevant blood tests at 12 weeks. This schedule is pragmatic, not trial-validated. Success means sustained appetite or body-composition change without compromised nutrition, strength, or tolerability; stable habits help interpret changes. Recording the product, daily dose, meal timing, and concurrent dietary or exercise changes provides context for comparing baseline with subsequent observations.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Body weight and waist No established thylakoid-specific target; track individual baseline and intended change Assess sustained effect Comparable morning conditions; weekly weights interpreted as trends, monthly waist measurements
Fasting glucose 80–89 mg/dL: Kresser’s practitioner preference; no validated thylakoid target Detect glucose change After an overnight fast; conventional normal upper limit is 99 mg/dL. Interpret with other markers; this narrower practitioner preference is not a universal treatment target
HbA1c 4.6–5.3%: Kresser’s practitioner range; no validated thylakoid target Longer-term glucose context Hemoglobin A1c (average blood glucose over several months); no fasting required. Conventional normal is below 5.7%; altered red-cell turnover can distort interpretation
Lipid panel No established extract-specific optimal range; track individual risk-based targets Assess lipid signal LDL already defined; lipid panel measures blood cholesterol and fats; consistent fasting conditions aid comparison when triglycerides are followed
Nutrient status No established supplement-specific target; track baseline and investigate restricted intake Detect nutritional compromise Blanket vitamin testing is unsupported; clinical context determines the particular test
Warfarin clotting test No established thylakoid-specific target; track the individual prescribed therapeutic range Detect altered anticoagulation Prescriber-defined monitoring after a supplement change; not routine in nonusers
  • Appetite and cravings: Ratings at consistent meals and times help distinguish sustained changes from daily variation.
  • Energy and strength: Meal completion, exercise performance, and unintended fatigue help detect under-fueling.
  • Tolerance: Digestive symptoms, headache, skin reactions, and intake changes matter despite unchanged laboratory values.

Emerging Research

  • Longer glucose trial: The Effect of Appethyl vs Placebo on Human Health, NCT05095038, enrolled 82 adults for 5 g/day over 26 weeks, targeting fasting glucose. It is terminated because collaborator funding stopped; no results are posted. This is unresolved evidence, not an ongoing trial or demonstrated failure.
  • Acute dose research: NCT02702245 compared 5 and 10 g during glucose-challenge testing in 21 adults. It is completed without posted results. Such data could clarify whether meal-related glucose responses strengthen or weaken the metabolic rationale.
  • Exercise context: Razi et al., 2026 found no clear added metabolic advantage over training alone in a small trial with substantial participant dropout. This limits expectations for already active adults despite exploratory changes in muscle-related blood markers.
  • Independent replication: Saeidi et al., 2023, Saeidi et al., 2024, and Abbassi-Daloii et al., 2025 share the same registered exercise cohort. Different marker reports do not independently confirm efficacy; separate cohorts could strengthen or weaken the observed signals.
  • Longevity relevance: Longer follow-up with clinical disease outcomes, nutritional safety, and independent replication could change the assessment. The Nikrad et al., 2025 meta-analysis establishes an appetite signal, leaving the connection to sustained health outcomes untested.

Conclusion

Thylakoids are plant membranes used in concentrated spinach extracts, with human research focused chiefly on appetite and weight management. Short-term hunger and fullness are the clearest measured benefits. Those changes are generally small, and feeling less hungry has not consistently translated into eating less or losing more body fat.

Weight, cholesterol, and glucose findings vary with the preparation, diet, population, and analysis. Favorable studies coexist with studies showing no added benefit and corrected results. Several recent papers come from the same participants, and adding an extract to structured exercise has not reliably produced extra improvements in blood sugar or cholesterol. For adults already maintaining strong nutrition and exercise habits, the likely value therefore centers on a possible appetite-management aid rather than an established improvement in long-term health.

Short studies report few symptoms, but they provide limited information about uncommon reactions, medication interactions, and prolonged use. Product composition matters, and appetite suppression may conflict with maintaining adequate intake and muscle. Early researchers’ links to Greenleaf Medical and Thylabisco, together with commercial supplement commentary, create potential bias that remains relevant to interpretation. The evidence supports a modest appetite effect with substantial uncertainty around broader benefits. Neither longer lifespan nor prevention of major age-related disease has been demonstrated.

Top - Benefits - Risks - Protocol